Direct-to-consumer skincare brand Be Clinical has successfully secured ₹21 crore, approximately $2.2 million, in a seed extension funding round. The investment was led by venture capital fund Sauce, with continued participation from existing backer V3 Ventures. This new capital injection is earmarked to accelerate the company's mission of providing science-backed anti-ageing solutions to Indian consumers.
Strategic Allocation of Capital
Be Clinical plans to strategically deploy the fresh funds to bolster its research and development capabilities and scale its manufacturing operations. The capital will also facilitate the expansion of its product portfolio across skin, body, and haircare categories. Furthermore, the investment will support the company's ambitious plans for entering new markets and geographies to broaden its consumer base.
A Science-First Approach to Skincare
Founded by Hemangi Dhir, Be Clinical distinguishes itself with a commitment to clinically tested formulations developed over two years of research. The brand focuses on using dermatologically active ingredients to address ageing concerns specifically for Indian skin types and conditions. This evidence-led approach ensures both the safety and efficacy of its products before they reach the market.
The company's in-house manufacturing setup provides significant control over product quality and effectiveness, a key differentiator in the market. Since its launch, the brand has demonstrated strong market traction by delivering over 1.2 lakh orders. This success is further underscored by a healthy rate of repeat purchases, indicating strong customer loyalty and satisfaction.
Investor Confidence and Market Position
Lead investor Sauce expressed confidence in Be Clinical's full-stack model, highlighting its in-house R&D and manufacturing as a genuine differentiator. Zoeb Ali Khan, Vice President at Sauce, noted that the brand is effectively capturing a shift in personal care towards longevity. V3 Ventures also doubled down on its investment, citing the company's impressive 5x sales growth while maintaining profitability.
The funding round also attracted a group of prominent angel investors, including the founders of Mokobara and senior executives from Reckitt. This follows a previous seed round of ₹6 crore led by V3 Ventures and an earlier infusion of ₹2 crore. This consistent backing from reputable investors underscores strong belief in the company's long-term vision and execution capabilities.
Navigating a Competitive Landscape
Be Clinical operates within a highly competitive beauty and personal care market, contending with both homegrown brands and established global players. The company's focus on clinically validated products aligns with a growing consumer demand for skincare solutions backed by scientific evidence. This trend provides a key avenue for emerging D2C brands to carve out a niche in a crowded industry.
The Indian beauty and personal care market, valued at over $31 billion in 2025, presents a substantial opportunity for growth. Projections indicate the market will expand to nearly $49 billion by 2034, reflecting robust consumer spending in the sector. Be Clinical's recent funding positions it well to capitalize on this expanding market and consumer preference for effective skincare.
This latest infusion of capital marks a significant milestone for Be Clinical, empowering the brand to enhance its product innovation and expand its reach. With a strengthened financial position and a clear focus on science-led skincare, the company is poised for its next phase of growth. The investment validates its unique market approach and strengthens its potential to become a leader in India's anti-ageing skincare segment.